Core Viewpoint - The company announced the presentation of preliminary data from its Phase I clinical study of CS2009 (a tri-specific antibody targeting PD1/VEGF/CTLA-4) and the design of the Phase Ib clinical study for CS5001 (a ROR1 antibody-drug conjugate) at the 2025 European Society for Medical Oncology (ESMO) annual meeting [1] Group 1 - The company is set to present its first clinical research data for CS2009 at a major oncology conference [1] - CS2009 is a tri-specific antibody that targets PD1, VEGF, and CTLA-4, indicating a novel approach in cancer treatment [1] - The design of the Phase Ib clinical study for CS5001 will also be unveiled, showcasing the company's ongoing research efforts in antibody-drug conjugates [1]

Core Viewpoint - Company shares of Basilea Pharmaceutica (02616) rose over 3%, currently trading at 6.99 HKD with a transaction volume of 15.38 million HKD, following the announcement of key clinical data to be presented at the upcoming ESMO conference in October 2025 [1] Group 1: Clinical Pipeline Updates - Basilea announced that its core clinical pipeline, CS2009 (a PD-1/VEGF/CTLA-4 tri-specific antibody), will present preliminary data from an ongoing Phase I dose-escalation study at the ESMO conference [1] - The abstract for CS2009 includes data from 9 patients as of the submission deadline on May 8, 2025, aimed at meeting ESMO's submission requirements [1] - The company will also showcase preliminary data from approximately 70 patients with advanced solid tumors for CS2009 in a poster presentation at the ESMO conference, marking the first known clinical data globally for a PD-1/VEGF/CTLA-4 tri-specific antibody [1] Group 2: Upcoming Events - The 2025 European Society for Medical Oncology (ESMO) annual meeting is scheduled to take place from October 17 to 21, 2025, in Berlin, Germany [1]

Core Viewpoint - The announcement highlights the upcoming presentation of clinical data for two key drug candidates, CS2009 and CS5001, at the 2025 ESMO annual meeting, marking significant milestones for the company in the oncology sector [1] Group 1: Clinical Trials and Data - The company will present preliminary data from the ongoing Phase I dose-escalation study of CS2009, a tri-specific antibody targeting PD-1, VEGF, and CTLA-4, involving approximately 70 patients with advanced solid tumors [1] - The abstract for CS2009 includes data from 9 patients as of the submission deadline on May 8, 2025, fulfilling ESMO's submission requirements [1] - The clinical data for CS5001, an antibody-drug conjugate targeting ROR1, will also be summarized in the ongoing Phase Ib study design [1]